Y Combinator is a startup accelerator that invests in a large number of startups twice a year. It created a new model for funding startups. Twice a year, the company invests a small amount of money ($150k) in a large number of startups. The startup accelerator works intensively with the companies for three months, to get them into the best possible shape and refine their pitch to investors. Each cycle culminates in Demo Day when the startups present their companies to a carefully selected, invite-only audience.

Y Combinator

BossaNova is the number one Brazilian Micro Venture Capital. We are the most active investor in the pre-seed stage in Latin America with more than 1200 investments in over 1000 Startups. We also invest in global companies, directly or through co-investment syndicates on AngelList.

Bossanova Investimentos

Kube VC is a global venture capital firm that invests in exceptional founders and category-defining companies.

Kube VC

Founded in 2014 by entrepreneurs Peng T. Ong and Kuo-Yi Lim, Monk’s Hill Ventures (‘MHV’) is a venture capital firm investing in early-stage technology startups in Southeast Asia. Backed by institutional investors and family offices worldwide, MHV works with great entrepreneurs to use technology to improve the lives of millions of people in the region. We take a first-principles approach in how we operate and make decisions at MHV. We break down ideas and business models to understand the fundamentals. Since our founding in 2014, Monk’s Hill Ventures has invested in more than 20 fast-growing startups spanning multiple business models and industry verticals. We look to work with founders in the early stages of the development of their businesses, and typically invest at the Series A stage.  We are entrepreneurs backing entrepreneurs. This runs in our DNA. With the utmost respect for the founder, the firm is led by entrepreneurs and operators, CEOs, and CTOs of successful tech companies both in Asia and in Silicon Valley. Our footprint spans across Southeast Asia with on-the-ground teams in Singapore, Indonesia, Malaysia, Vietnam and Thailand. Our network comprises entrepreneurs, investors, former CEOs, engineers, academics, media and a team of operating advisors with strong domain expertise from cybersecurity, data science, financial services, to healthcare, to provide our founders with the right access and advice as they scale and build.

Monk’s Hill Ventures

Golden Gate Ventures is a SouthEast Asian venture capital firm founded in 2011 that brings together knowledge and experience from Silicon Valley with passion and ambition for Southeast Asia. For over a decade we've proudly backed some of the region's most audacious founders and had the privilege of being part of Southeast Asia’s incredible growth story. Headquartered in Singapore with offices in Indonesia and Vietnam We’ve launched 4 funds, have US$250M AUM, and invested in 70+ companies with 9 unicorns across our portfolio.

Golden Gate Ventures

Healthcare and life sciences investment firm

Anthro Ventures

Hannah Life Technologies

Hannah Life Technologies is changing the infertility treatment landscape by developing new, groundbreaking and safe fertility products. Alumni of the Stanford Biodesign Fellowship program founded the company to address critical unmet needs in infertility treatment. A Scientific Advisory Board consisting of leading fertility clinicians advise the company.

Hannah Life Technologies (Hannah) offers a flexible, silicone-based vaginal insert device that increases the concentration of sperm into the cervical opening, maximizing the number of sperm that meets the egg.

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

Fertility startup Hannah Life Technologies gets $5.15M Pre-Series A

Hannah Life Technologies (Hannah) offers a flexible, silicone-based vaginal insert device that increases the concentration of sperm into the cervical opening, maximizing the number of sperm that meets the egg.When compared to other treatments like intrauterine insemination (IUI), Hannah’s device is non-invasive, increases the chance of natural conception at home, and sends sperm through cervical mucus (unlike IUI) which can filter unhealthy sperm. Moreover, the company claims Hannah’s device should cost only 10-20% of the cost of an IUI cycle. Hannah was part of Y Combinator’s startup accelerator program, in Summer 2020, and its device was in closed beta as of December 2020.Hannah reported revenue growth of over 300% quarter-over-quarter (QoQ) between August 2021 to May 2022, and it served more than thousands of households in Singapore and the UK, as of May 2022.In May 2022, the company <a href="https://sp-edge.com/updates/10257?industryIds=40">raised USD 5.15 million </a>in a pre-Series A funding round led by Monk’s Hill Ventures. The funds were expected to be utilized to increase its employee headcount and to expand its sales and marketing efforts in the US and Europe.

<div>
 
 Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing. 
 
 
 Glow generated around USD 0.3 million monthly revenue in October 2020, and as of February 2019 it had around 15 million users, and claims to have helped about 950,000 women get pregnant (from May 2013 to February 2019). In February 2019 Glow partnered with US Match Group (provider of dating products such as Match.com and Tinder), to provide Match’s employees with egg freezing benefits at reputed fertility clinics. In May 2017 it partnered with the National Institute of Health (NIH) to update a prediction model for couples trying to conceive.  
 
 
 In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.
 
 
 
</div>

Glow

<div>
 
 Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.
 
 
 Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.
 
 
 In May 2022, Inne 
 <a href="https://sp-edge.com/updates/10667?industryIds=40">
 raised USD 10 million
 </a>
 in an extension to its Series A round led by DSM Venturing. The company utilized the funds to continue the development of its mini lab and platform, grow its team, and support its expansion across the US, where it aims to enter with its perimenopause feature, followed by an expanded product launch in late 2022.
 
 
 
</div>

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.As of May 2021, it was the only FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test, and its method of determining the fertile window was patented. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.In June 2020, the company received a USD 1.3 million deal from the US Air Force, to provide Proov kits to enrolled individuals. The Proov test was distributed through leading US retailers such as Target and Amazon, and was also used by doctors across the country.Proov raised USD 9.7 million in Series A funding in December 2021, in a round led by Hambrecht Ducera Growth Ventures, with participation from other venture capital firms such as SteelSky Ventures, WCC Partners, and Lightship Capital, among others. The company expects to use the funding to grow its “Complete” product, which includes follicle-stimulating hormone tests and other multi-hormone tests that measure estrone glucuronide, LH and PdG.

Proov

<div>
 
 Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.
 
 
 The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.
 
 
 Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.
 
 
 Funding and financials
 
 
 In October 2019, Progyny raised USD 130 million through its IPO, where it was listed on the Nasdaq.
 
 
 In FY2021, the company reported a revenue of USD 500.6 million reflecting a 45% YoY growth and a net income of USD 65.8 million. The company&rsquo;s revenue for 
 <a href="https://sp-edge.com/updates/14396">
 Q3 FY2022
 </a>
 amounted to USD 205.4 million, representing 68% YoY growth. The management&rsquo;s revenue guidance for FY2022 ranges between USD 775 million and USD 785 million, which implies an YoY growth of 55% to 57%.
 
</div>

Progyny

<div>
 
 Prima Temp offers the artificial intelligence (AI) assisted “Priya” intarvaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility related education and links users to a community of over 140,000 members.  
 
 
 The company raised USD 5 million in funding in May 2019 from Gedeon Richter, a Hungarian pharmaceutical company. Although the company primarily focuses on fertility monitoring, it intends to expand its offerings to include other areas of fertility management such as contraception and menopause.  
 
 
 
 
 
</div>

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

Hannah Life Technologies

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless